Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ASND

Ascendis Pharma A/S

270.45

Jul 10 • 04:00PM ET -4.98 (-1.81%)

Healthcare Biotechnology Denmark Large NASD

Peers: BMRN VRTX IONS REGN ALNY EXEL INCY RARE CRSP NBIX

| Held by: IBB TCAF IWP IWR IWF SQS FXH SPDW AFOS FDG

Scroll to Statements

Index	-
Market Cap	16.80B
Enterprise Value	17.17B
Income	581.90M
Sales	1.01B
Book/sh	9.05
Cash/sh	10.63
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Jan 28, 2015

P/E	30.48
Forward P/E	24.90
PEG	-
P/S	16.71
P/B	29.88
P/C	25.45
P/FCF	332.17
EV/EBITDA	1270.97
EV/Sales	17.08
Quick Ratio	0.72
Current Ratio	1.00
Debt/Eq	1.84
LT Debt/Eq	0.79
Option/Short	Yes / Yes

EPS (ttm)	8.87
EPS next Y	10.86
EPS next Q	1.73
EPS this Y	455.71%
EPS next Y	-28.98%
EPS next 5Y	-
EPS past 3/5Y	27.03% 14.76%
Sales past 3/5Y	147.23% 152.45%
EPS Y/Y TTM	249.36%
Sales Y/Y TTM	155.14%
EPS Q/Q	787.72%
Sales Q/Q	171.53%
Earnings	May 07 BMO
EPS/Sales Surpr.	5921.98% -7.60%

Insider Own	0.89%
Insider Trans	-3.19%
Inst Own	102.13%
Inst Trans	-41.64%
ROA	33.69%
ROE	325.80%
ROIC	57.78%
Gross Margin	87.35%
Oper. Margin	-0.66%
Profit Margin	57.88%
SMA20	8.01%
SMA50	13.47%
SMA200	21.73%
Trades

Shs Outstand	62.11M
Shs Float	61.56M
Short Float	5.32%
Short Ratio	4.18
Short Interest	3.28M
52W High	282.15 -4.15%
52W Low	160.86 68.13%
Volatility	3.38% 4.25%
ATR (14)	9.84
RSI (14)	65.40
Beta	0.37
Rel Volume	0.48
Avg Volume	783.72K
Volume	375,408

Perf Week	-1.48%
Perf Month	26.83%
Perf Quarter	11.89%
Perf Half Y	26.81%
Perf YTD	26.83%
Perf Year	53.24%
Perf 3Y	204.22%
Perf 5Y	114.56%
Perf 10Y	1983.59%
Recom	1.10
Target Price	294.93
Prev Close	275.43
Price	270.45
Change	-1.81%

Date	Action	Analyst	Rating Change	Price Target Change
May-19-26	Initiated	Citigroup	Buy	$355
Mar-16-26	Resumed	Jefferies	Buy
Jan-28-26	Initiated	Barclays	Overweight	$342
Nov-18-25	Initiated	Wolfe Research	Peer Perform	$255
Oct-17-25	Initiated	Raymond James	Strong Buy	$271
Jul-03-25	Resumed	Morgan Stanley	Overweight	$250
May-05-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$250
Apr-16-25	Initiated	RBC Capital Mkts	Outperform	$205
Jan-07-25	Initiated	UBS	Buy	$196
Sep-05-24	Upgrade	Oppenheimer	Perform → Outperform	$180
Jun-25-24	Upgrade	TD Cowen	Hold → Buy	$156 → $175
May-31-24	Initiated	Stifel	Buy	$200
Dec-20-23	Initiated	Jefferies	Buy	$150
Jun-14-23	Resumed	Credit Suisse	Neutral	$89
Apr-05-23	Downgrade	Oppenheimer	Outperform → Perform
Apr-04-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$151 → $108
Apr-03-23	Downgrade	Credit Suisse	Outperform → Neutral
Oct-20-22	Initiated	Goldman	Buy	$174
Aug-30-22	Resumed	Berenberg	Buy	$166
Mar-28-22	Resumed	Wedbush	Outperform	$163

Show Previous Ratings

Jun-30-26 08:30AM	Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial (GlobeNewswire)
Jun-26-26 04:01PM	Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000, Russell 1000, Russell 2500 and Russell Midcap (GlobeNewswire)
Jun-25-26 04:01PM	Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026 (GlobeNewswire) +9.90%
Jun-13-26 04:00PM	Phase 3 Data Show TransCon PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism (GlobeNewswire)
Jun-11-26 04:01PM	5-Year Phase 2 Data Show TransCon PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism (GlobeNewswire)
04:59PM	Loading…
Jun-08-26 04:59PM	Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026 (GlobeNewswire)
May-28-26 04:27PM	JPMorgan says large-cap biotech is back as profits and pipelines fuel upside (Investing.com) -5.63%
May-20-26 03:29PM	JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms (Investing.com)
May-19-26 09:34AM	StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls (The Fly)
May-07-26 07:30AM	Ascendis Pharma Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-06-26 04:01PM	New 2-Year Data from Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged =5 Years (GlobeNewswire)
Apr-30-26 04:01PM	Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026 (GlobeNewswire)
Apr-21-26 04:31PM	Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028 (GlobeNewswire)
Apr-20-26 08:00AM	Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq (GlobeNewswire)
Apr-08-26 12:00PM	Ascendis Pharma to List Ordinary Shares Directly on Nasdaq (GlobeNewswire) +5.77%
08:01AM	Loading…
08:01AM	New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon hGH Accelerated TransCon CNP's Benefits Beyond Linear Growth in Children with Achondroplasia (GlobeNewswire)
Apr-06-26 04:01PM	Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL (Navepegritide) in the United States (GlobeNewswire)
Mar-17-26 08:30AM	New InsiGHTS Trial of TransCon hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 (GlobeNewswire)
Mar-16-26 08:00AM	New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026 (GlobeNewswire)
Mar-04-26 10:32PM	Ascendis Pharma Details Early Q2 YUVIWEL Launch Plan, Pricing Tease at TD Cowen Conference (MarketBeat)
09:54PM	Ascendis Pharma Maps 2026 U.S. Launch of Once-Weekly YUVIWEL After FDA Approval in Achondroplasia (MarketBeat)
01:24PM	This Biopharma Stock Flirts With Buy Point After New FDA Approval (Investor's Business Daily)
05:45AM	Ascendis Wins FDA Approval For Rare Disease Therapy (Benzinga)
Mar-02-26 08:43AM	Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
08:02AM	Ascendis Wins FDA Approval For Rare Disease Therapy (Benzinga)
07:22AM	Ascendis wins FDA approval of dwarfism drug (BioPharma Dive)
Feb-27-26 05:57PM	FDA Approves Once-Weekly YUVIWEL (navepegritide) for Children with Achondroplasia Aged 2 Years and Older (GlobeNewswire)
Feb-20-26 04:10AM	Ascendis Pharma (ASND) Revenue Nearly Doubles to 720M in 2025 Fueled by Core Product Growth (Insider Monkey)
Feb-12-26 12:44PM	BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 (Benzinga)
12:23PM	Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor (BioPharma Dive)
12:03AM	Loading…
12:03AM	Ascendis Pharma AS (ASND) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-11-26 06:39PM	Ascendis Pharma A/S Q4 Earnings Call Highlights (MarketBeat)
04:01PM	Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
Feb-04-26 04:01PM	Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026 (GlobeNewswire)
Jan-30-26 02:07AM	RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets (Insider Monkey)
Jan-29-26 03:01PM	BofA Reiterates Buy Rating on Ascendis Pharma (ASND) While Wells Fargo Analyst Raises PT (Insider Monkey)
Jan-26-26 10:14AM	Allstate Upgraded, Amazon Downgraded: Updated Rankings on Top Blue-Chip Stocks (InvestorPlace)
Jan-15-26 01:03PM	Ascendis Pharma A/S (ASND): A Bull Case Theory (Insider Monkey)
Jan-14-26 06:14AM	Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains? (Zacks)
Jan-12-26 07:02PM	Ascendis Pharma A/S Touts 683M Product Revenue, Feb PDUFA Catalyst at JPM Healthcare Conference (MarketBeat)
Jan-09-26 06:01PM	Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-26 11:03PM	Ascendis Pharma COACH Week 52 data show combo TransCon CNP + hGH boosts growth in achondroplasia (MarketBeat)
04:01PM	Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) (GlobeNewswire)
Jan-05-26 08:30AM	Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-25 09:42AM	Ford Upgraded, Amazon Downgraded: Updated Rankings on Top Blue-Chip Stocks (InvestorPlace)
Dec-11-25 10:37AM	Eight stock picks to play one of the healthiest corners of the market (MarketWatch)
Dec-04-25 11:10AM	The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch. (Barrons.com)
Nov-26-25 05:47AM	Novartis cuts hundreds of jobs; Novos dual-acting diabetes drug heading to Phase 3 (BioPharma Dive)
Nov-25-25 06:15PM	Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia (GlobeNewswire)
Nov-17-25 04:01PM	Results of Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics (GlobeNewswire) +5.95%
Nov-13-25 12:00AM	Ascendis Pharma AS (ASND) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Nov-12-25 04:01PM	Ascendis Pharma Reports Third Quarter 2025 Financial Results (GlobeNewswire)
07:54AM	MDT Q2 Earnings Preview: Cardiovascular Unit Likely to Boost Growth (Zacks)
05:25AM	Cisco Systems headlines earnings slate (MarketWatch)
03:51AM	Stock Market Today: Dow consolidates after 3-day 1,000-point surge to record high, S&P 500 and Nasdaq called higher as Treasury yields dip; Cisco earnings on tap. (MarketWatch)
Nov-10-25 11:21AM	Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? (Zacks)
Nov-07-25 08:30AM	New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism (GlobeNewswire)
Nov-05-25 04:01PM	Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025 (GlobeNewswire) -5.04%
Nov-03-25 04:01PM	3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025 (GlobeNewswire)
Oct-13-25 12:29PM	Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks (InvestorPlace)
Oct-08-25 04:01PM	Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon CNP for Treatment of Children with Achondroplasia (GlobeNewswire)
Oct-07-25 09:40AM	Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock? (Zacks)
Oct-02-25 01:35AM	UBS Maintains Buy on Ascendis (ASND), Sees Upside from Yorvipath Data (Insider Monkey)
Sep-24-25 02:12AM	Bank of America Securities Reiterates a Buy on Ascendis Pharma (ASND) (Insider Monkey)
Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-14-25 01:16AM	Morgan Stanley Remains Bullish on Ascendis Pharma (ASND) (Insider Monkey)
Sep-02-25 04:01PM	Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025 (GlobeNewswire)
Aug-28-25 04:01PM	Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-12-25 10:56AM	Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players (GlobeNewswire)
Aug-07-25 04:01PM	Ascendis Pharma Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 04:01PM	Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 (GlobeNewswire)
Jul-28-25 07:00AM	FDA Approves SKYTROFA (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency (GlobeNewswire)
Jul-24-25 11:47PM	Ascendis Pharma A/S (ASND) Delivers Positive Trial Results for Hypoparathyroidism Treatment (Insider Monkey)
Jul-22-25 10:50AM	Phase II and Phase III Catalyst Monitor: Q3 2025 Outlook Report - Upcoming FDA Decisions Drive Momentum in Biopharma with Key Catalysts Across GHD, PKU, Presbyopia, and Wet AMD Treatments (GlobeNewswire)
Jul-16-25 09:55AM	Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade (Zacks)
Jul-14-25 04:01PM	New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life (GlobeNewswire)
Jul-07-25 04:01PM	Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025 (GlobeNewswire)
Jun-24-25 04:25AM	Oppenheimer Hikes Ascendis Pharma Price Target on Strong Yorvipath Demand Outlook (Insider Monkey)
Jun-14-25 08:40AM	Ascendis Pharma price target raised to $224 from $215 at Oppenheimer (TipRanks)
Jun-11-25 07:43PM	TransCon hGH Boosts TransCon CNP Results in Kids with Achondroplasia by Week 26 (Insider Monkey)
Jun-10-25 10:39AM	Ascendis reports interim analysis outcomes from achondroplasia trial (Clinical Trials Arena)
Jun-09-25 07:00AM	TransCon hGH Boosted Treatment Benefits of TransCon CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial (GlobeNewswire)
Jun-02-25 08:00AM	FDA Accepts TransCon CNP NDA for Priority Review (GlobeNewswire) +7.89%
May-13-25 10:13PM	Ascendis Pharma A/S (ASND): Among the Best Growth Stocks to Buy and Hold for the Long Term (Insider Monkey)
04:01PM	New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon CNP (Navepegritide) (GlobeNewswire)
May-12-25 04:45PM	New 4-Year Data Shows Sustained Response to TransCon PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism (GlobeNewswire)
May-07-25 08:00AM	Rare Stock Picks In April 2025 - From 16 Discerning Analysts (Seeking Alpha)
May-06-25 08:08AM	Launch of New Drug Lifted Ascendis Pharma A/S (ASND) in Q1 (Insider Monkey)
May-05-25 08:30AM	Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025 (GlobeNewswire)
May-02-25 03:17AM	Ascendis Pharma AS (ASND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ... (GuruFocus.com)
May-01-25 09:35PM	Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript (Seeking Alpha)
04:01PM	Ascendis Pharma Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 02:29PM	Growth Is Priced Out Of Novo Nordisk (Seeking Alpha)
Apr-24-25 04:01PM	Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025 (GlobeNewswire)
01:15AM	Artisan Mid Cap Fund Q1 2025 Commentary (Seeking Alpha)
Apr-17-25 11:00AM	Reddit initiated, Target downgraded: Wall Streets top analyst calls (TipRanks)
Apr-16-25 09:40AM	Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year? (Zacks)
Apr-14-25 04:38PM	Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory (Seeking Alpha)
02:03PM	Is Ascendis Pharma A/S (ASND) the Best Growth Stock to Buy According to Billionaires? (Insider Monkey)
Mar-31-25 04:01PM	Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia (GlobeNewswire)

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.

PresidentMr. Jan Moller Mikkelsen

CFOMr. Scott T. Smith

Executive VPMs. Pedersen Anni Lotte Kirstine Sonderbjerg

Executive VPMr. Michael Wolff Jensen L.L.M.

Senior VPMr. Mads Bodenhoff

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SMITH SCOTT THOMAS	EVP & Chief Financial Officer	Jun 02 '26	Buy	219.00	100	21,900	4,367	Jun 02 04:25 PM
BIENAIME JEAN JACQUES	Director	May 29 '26	Buy	223.12	500	111,562	900	Jun 01 04:11 PM
SMITH SCOTT THOMAS	EVP & Chief Financial Officer	May 29 '26	Buy	223.32	250	55,830	4,267	Jun 01 04:10 PM
BIENAIME JEAN JACQUES	Director	May 26 '26	Buy	237.80	400	95,120	400	May 27 04:05 PM
JENSEN FLEMMING STEEN	See Remarks	May 11 '26	Sale	238.49	19,460	4,641,021	0	May 12 04:08 PM
JENSEN FLEMMING STEEN	Officer	May 11 '26	Proposed Sale	238.49	19,460	4,641,022		May 11 03:36 PM
SINGEL STINA	Officer	Mar 09 '26	Proposed Sale	240.00	3,782	907,680		Mar 09 05:30 PM
Bodenhoff Mads	Officer	Mar 06 '26	Proposed Sale	237.53	10,000	2,375,308		Mar 06 04:21 PM
Shu Aimee	Officer	Mar 05 '26	Proposed Sale	235.81	5,583	1,316,555		Mar 05 05:20 PM
SMITH SCOTT THOMAS	Officer	Mar 05 '26	Proposed Sale	240.00	10,000	2,400,000		Mar 05 05:07 PM
Jan Moller Mikkelsen	CEO	Mar 05 '26	Proposed Sale	241.38	94,000	22,689,720		Mar 05 05:04 PM
Morrison Lisa	Officer	Mar 04 '26	Proposed Sale	236.34	10,105	2,388,195		Mar 04 04:58 PM
Shu Aimee	Officer	Mar 04 '26	Proposed Sale	239.22	7,290	1,743,914		Mar 04 10:54 AM
Fairey William	Director	Mar 02 '26	Proposed Sale	242.09	1,800	435,762		Mar 02 05:01 PM
IMANI SIHAM	Director	Mar 02 '26	Proposed Sale	242.09	1,800	435,762		Mar 02 04:59 PM
SMITH SCOTT THOMAS	Officer	Mar 02 '26	Proposed Sale	242.09	18,349	4,442,109		Mar 02 04:56 PM
JENSEN MICHAEL WOLFF	Officer	Mar 02 '26	Proposed Sale	242.09	18,349	4,442,109		Mar 02 04:52 PM
Bodenhoff Mads	Officer	Mar 02 '26	Proposed Sale	242.09	6,872	1,663,642		Mar 02 04:44 PM
PEDERSEN ANNI LOTTE KIRSTINE S	Officer	Mar 02 '26	Proposed Sale	242.09	10,800	2,614,572		Mar 02 04:40 PM
Morrison Lisa	Director	Mar 02 '26	Proposed Sale	242.09	2,100	508,389		Mar 02 04:35 PM
HOLTUG LARS	Director	Mar 02 '26	Proposed Sale	242.09	2,100	508,389		Mar 02 04:32 PM
SPROGOE KENNETT	Officer	Mar 02 '26	Proposed Sale	242.09	10,800	2,614,572		Mar 02 04:27 PM
JENSEN FLEMMING STEEN	Officer	Mar 02 '26	Proposed Sale	242.09	10,800	2,614,572		Mar 02 04:23 PM
Cha Albert	Director	Mar 02 '26	Proposed Sale	242.09	2,100	508,389		Mar 02 04:18 PM
MIKKELSEN JAN MOLLER	Officer	Jan 13 '26	Proposed Sale	211.99	86,860	18,413,631		Jan 13 02:01 PM
JENSEN MICHAEL WOLFF	Officer	Dec 04 '25	Proposed Sale	208.10	10,000	2,081,019		Dec 04 05:07 PM
Jan Moller Mikkelsen	CEO	Dec 02 '25	Proposed Sale	210.85	100,000	21,085,000		Dec 02 05:04 PM
SPROGOE KENNETT	Officer	Dec 02 '25	Proposed Sale	209.32	10,000	2,093,222		Dec 02 04:54 PM
JENSEN FLEMMING STEEN	Officer	Dec 02 '25	Proposed Sale	205.85	10,000	2,058,454		Dec 02 04:43 PM
SINGEL STINA	Officer	Dec 01 '25	Proposed Sale	209.54	218	45,680		Dec 01 02:30 PM
JENSEN FLEMMING STEEN	Officer	Sep 09 '25	Proposed Sale	203.70	5,000	1,018,503		Sep 09 04:12 PM
JENSEN MICHAEL WOLFF	Officer	Aug 29 '25	Proposed Sale	193.00	5,000	965,000		Aug 29 04:00 PM
PEDERSEN ANNI LOTTE KIRSTINE S	Officer	Aug 27 '25	Proposed Sale	193.94	3,036	588,814		Aug 27 04:06 PM
Jan Moller Mikkelsen	President and Chief Executive	Aug 20 '25	Proposed Sale	192.79	3,000	578,385		Aug 20 05:34 PM
JENSEN MICHAEL WOLFF	Officer	Aug 15 '25	Proposed Sale	194.82	9,375	1,826,403		Aug 15 04:15 PM
PEDERSEN ANNI LOTTE KIRSTINE S	Officer	Aug 14 '25	Proposed Sale	191.60	25,000	4,789,998		Aug 14 04:13 PM
JENSEN FLEMMING STEEN	Officer	Aug 13 '25	Proposed Sale	191.32	10,000	1,913,225		Aug 13 05:18 PM
Morrison Lisa	Director	Aug 13 '25	Proposed Sale	191.07	2,158	412,319		Aug 13 04:22 PM
SMITH SCOTT THOMAS	Officer	Aug 12 '25	Proposed Sale	192.57	10,000	1,925,734		Aug 12 05:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ASND

Ascendis Pharma A/S

Upgrade your Finviz experience